Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

149.50 +1.42 (+0.96%)

Streaming Delayed Price Updated: 1:59 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

56 57 Next >

Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz ↗

August 24, 2023

CVS Health Corp (NYSE: CVS) has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar

Via Benzinga

Could This Medicine Be the Next Winner for Novartis? ↗

August 23, 2023

The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.

Via The Motley Fool

Gold Rush In Weight Loss Industry Impacts Retailers With Pharmacy Businesses ↗

August 22, 2023

Retailers with pharmacy businesses, including major players like Walmart Inc (NYSE: WMT), Kroger Company (NYSE: KR), and Rite Aid Corp (NYSE:

Via Benzinga

A Comprehensive Study Exploring Breast Cancer Drugs Market : Key Players- Sanofi, Novartis, Lilly ↗

August 21, 2023

The Global Breast Cancer Drugs Market offers energetic visions to conclude market size, opportunities, growth pattern, and competitive surroundings. The research is derived through primary and...

Via SBWire

Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms ↗

August 21, 2023

The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.

Via Investor's Business Daily

2 Excellent Stocks to Buy and Hold Forever ↗

August 17, 2023

These companies have solid long-term potential.

Via The Motley Fool

2 Top Biotech Stocks to Buy Right Now ↗

August 14, 2023

These drugmakers are among the most dominant in the world.

Via The Motley Fool

DTx Pharma Acquisition by Novartis Generates Robust Returns for Tech Coast Angels and NuFund Venture Group

August 03, 2023

IRVINE, Calif. - Aug. 3, 2023 - PRLog -- Tech Coast Angels (TCA) and NuFund Venture Group (formerly TCA-San Diego) today announced that portfolio company DTx Pharma was acquired by Swiss pharmaceutical...

Via PRLog

SpaceX On Par With Intel, Disney; US Weight Loss Drugs Pricier; Moderna, Pfizer's Shot Effective Against New Variant: Today's Top Stories ↗

August 18, 2023

Benzinga

Via Benzinga

Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients ↗

August 18, 2023

Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible

Via Benzinga

Novartis' Generic Business Spinoff: Plans Sandoz Spin-Off In Early October, Proposes Share Distribution ↗

August 18, 2023

Novartis AG (NYSE: NVS)

Via Benzinga

COPD & Asthma Devices Market to Witness Remarkable Growth by 2029 : Pfizer, GSK, Novartis, Merck ↗

August 17, 2023

Stay up to date with COPD & Asthma Devices Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Addiction Treatment Market May See New Emerging Trends: Novartis, Pfizer, Sanofi ↗

August 17, 2023

Pune, Maharashtra -- (SBWIRE) -- 08/17/2023 -- 2023-2031 Report on Global Addiction Treatment Market by Player, Region, Type, Application and Sales Channel is the latest research study released by HTF...

Via SBWire

Should Income Investors Buy This Blue Chip Stock? ↗

July 23, 2023

This Swiss drugmaker is one of the most dominant players in its industry.

Via The Motley Fool

Essential Thrombocythemia Market Projected to Show Strong Growth : Pharmaessentia, Bristol Myers Squibb, Shire

August 14, 2023

Get an extensive Essential Thrombocythemia Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

3 Unstoppable Dividend Stocks to Buy Right Now ↗

August 12, 2023

These stocks' dividends are more dependable than most.

Via The Motley Fool

Immuno Oncology Market May See a Big Move : AstraZeneca, Bristol Myers Squibb, F. Hoffmann-La Roche

August 09, 2023

Stay up-to-date with Immuno Oncology Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Novartis's Remibrutinib Shows Rapid Improvement In Type Of Skin Disorder That Impacts 40M People ↗

August 09, 2023

Novartis AG (NYSE: NVS)

Via Benzinga

Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA

August 08, 2023

Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Multiple Myeloma Therapy Market Projected to Show Strong Growth : Hikma Pharmaceutical, Eagle Pharmaceuticals, Janssen Biotech

August 08, 2023

Get Multiple Myeloma Therapy Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.

Via SBWire

The Year’s Top 3 International ETFs as of August 2023 ↗

August 07, 2023

By investing in international ETFs, you can mitigate potential losses with a more diversified portfolio. Here are three with strong returns.

Via InvestorPlace

Blockbuster Drugs Market Projected to Show Strong Growth : Celgene, Bristol-Myers Squibb, Pfizer

August 03, 2023

Get an extensive Blockbuster Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Topics Intellectual Property

7 Best Cancer Stocks to Invest in Now

July 28, 2023

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

Via MarketBeat

Topics Death

3 Biotech Stocks You Better Be Buying on Each and Every Dip ↗

July 27, 2023

Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.

Via InvestorPlace

2 Stocks That Raised Their Guidance in July ↗

July 26, 2023

With inflation elevated, these are relatively resilient businesses to invest in.

Via The Motley Fool

Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries ↗

July 26, 2023

Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling

Via Benzinga

The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos ↗

July 24, 2023

With global events only rising in entropy, investors ought to consider these best dividend stocks for portfolio protection.

Via InvestorPlace

AI for Pharma and Biotech Market May Set Massive Growth by 2030

July 24, 2023

Get a view on AI for Pharma and Biotech Market sales by marketing channels. Target important market by region and tap important dynamics of this industry.

Via SBWire

Topics Artificial Intelligence

Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush

July 24, 2023

A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies.

Via MarketBeat

Week In Review: Novartis In $1 Billion Deal For DTx Pharma ↗

July 22, 2023

Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching...

Via Talk Markets

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today